Drug Trial Radar · NCT03850574
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Last checked: Nov 20, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Mar 11, 2019
Primary completion
Nov 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Aptose Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study.
Conditions
- Leukemia, Myeloid, Acute
- Refractory AML
- Relapsed Adult AML
- Myelodysplastic Syndrome With Excess Blasts-2
- Chronic Myelomonocytic Leukemia
Interventions
TuspetinibDrug
Daily (QD), continuous dosing
Venetoclax Oral TabletDrug
Venetoclax will be given to study participants in the Part C tuspetinib plus venetoclax combination treatment group either in 50 mg or 100 mg tablets
Azacitidine for Intravenous InfusionDrug
Azacitidine will be given to study participants in Part D as intravenous infusion at a dose of 75 mg/m\^2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of drug-related adverse eventsTime frame: 4 years
- Maximum tolerated dose (MTD) of tuspetinibTime frame: 4 years
- Maximum plasma concentration (Cmax)Time frame: Cycle 1 (at least 28 days)
- Minimum plasma concentration (Cmin)Time frame: Cycle 1 (at least 28 days)
- Area under the plasma concentration-time curve (AUC)Time frame: Cycle 1 (at least 28 days)
- Time to maximum concentration (Tmax)Time frame: Cycle 1 (at least 28 days)
- Terminal half-life (t1/2)Time frame: Cycle 1 (at least 28 days)
- Volume of distributionTime frame: Cycle 1 (at least 28 days)
- Plasma clearance (CL)Time frame: Cycle 1 (at least 28 days)
- Recommended Phase 2 dose (RP2D) of tuspetinibTime frame: 4 years
Locations
34 sites in 6 countries. Site status is shown where the registry gives one.
The Kirklin Clinic of UAB Hospital
Birmingham, Alabama · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Active not recruiting
University of California Irvine
Irvine, California · Recruiting
UCSD Moores Cancer Center
La Jolla, California · Active not recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Stanford Cancer Center
Palo Alto, California · Recruiting
University of California, Davis
Sacramento, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
University of Miami - Miller School of Medicine
Miami, Florida · Recruiting
Emory University
Atlanta, Georgia · Active not recruiting
Massachusetts General Hospital
Boston, Massachusetts · Active not recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Cleveland Clinic - Taussig Cancer Center
Cleveland, Ohio · Active not recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
MD Anderson Cancer Center
Huston, Texas · Recruiting
Border Medical Oncology
Albury, New South Wales, Australia · Active not recruiting
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia · Active not recruiting
Townsville University Hospital
Townsville, Queensland, Australia · Active not recruiting
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia · Active not recruiting
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia · Active not recruiting
Universitätsklinikum Leipzig
Leipzig, Saxony, Germany · Active not recruiting
Charité Universitätsmedizin Berlin
Berlin, State of Berlin, Germany · Active not recruiting
Auckland City Hospital
Grafton, Auckland, New Zealand · Active not recruiting
Kyungpook National University Hospital
Daegu, South Korea · Active not recruiting
Pusan National University Hospital
Pusan, South Korea · Active not recruiting
Seoul National University Bundang Hospital
Seongnam, South Korea · Active not recruiting
Seoul National University Hospital
Seoul, Seoul, South Korea · Completed
Asan Medical Center
Seoul, Seoul, South Korea · Active not recruiting
Samsung Medical Center
Seoul, Seoul, South Korea · Active not recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Barcelona, Spain · Active not recruiting
Hospital Quirón Madrid
Pozuelo de Alarcón, Madrid, Spain · Active not recruiting
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain · Active not recruiting
Hospital Clinico Universitario de Valencia
Valencia, Valencia, Spain · Active not recruiting
Hospital Universitari i Politècnic La Fe
Valencia, Valencia, Spain · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.